Ilaria Girolami1, Liron Pantanowitz2, Enrico Munari3, Maurizio Martini4, Riccardo Nocini5, Nicola Bisi5, Gabriele Molteni5, Daniele Marchioni5, Claudio Ghimenton1, Matteo Brunelli1, Albino Eccher1. 1. Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy. 2. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 3. Department of Pathology, Sacro Cuore Don Calabria Hospital, Italy. 4. Division of Anatomic Pathology and Histology, Catholic University-Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. 5. Department of Otorhinolaringology and Head & Neck Surgery, University and Hospital Trust of Verona, Verona, Italy.
Abstract
BACKGROUND: Studies concerning programmed death-ligand 1 (PD-L1) expression in precancerous lesions of head and neck (HN) region have shown variable results. METHODS: We systematically reviewed the published evidence on PD-L1 expression in HN precancerous lesions. RESULTS: Of 1058 original articles, 14 were included in systematic review and 9 in meta-analysis. The pooled estimate of PD-L1 expression was 48.25% (confidence interval [CI] 21.07-75.98, I2 98%, tau2 0.18). PD-L1 expression appeared to be more frequent in precancerous lesions than in normal mucosa (risk ratio [RR] 1.65, CI 0.65-4.03, I2 91%, tau2 0.82) and less frequent than in invasive squamous cell carcinoma (RR 0.68, CI 0.43-1.08, I2 91%, tau2 0.22). CONCLUSIONS: PD-L1 expression could reflect a point of balance between host immune response and cancer escape ability. High heterogeneity and moderate quality suggest that further studies with larger sample size and more rigorous case selection will allow more precise assessment of PD-L1 expression in HN precancerous lesions.
BACKGROUND: Studies concerning programmed death-ligand 1 (PD-L1) expression in precancerous lesions of head and neck (HN) region have shown variable results. METHODS: We systematically reviewed the published evidence on PD-L1 expression in HN precancerous lesions. RESULTS: Of 1058 original articles, 14 were included in systematic review and 9 in meta-analysis. The pooled estimate of PD-L1 expression was 48.25% (confidence interval [CI] 21.07-75.98, I2 98%, tau2 0.18). PD-L1 expression appeared to be more frequent in precancerous lesions than in normal mucosa (risk ratio [RR] 1.65, CI 0.65-4.03, I2 91%, tau2 0.82) and less frequent than in invasive squamous cell carcinoma (RR 0.68, CI 0.43-1.08, I2 91%, tau2 0.22). CONCLUSIONS:PD-L1 expression could reflect a point of balance between host immune response and cancer escape ability. High heterogeneity and moderate quality suggest that further studies with larger sample size and more rigorous case selection will allow more precise assessment of PD-L1 expression in HN precancerous lesions.
Authors: Juan Carlos Cuevas-González; Maria Veronica Cuevas-González; Leon Francisco Espinosa-Cristobal; Alejandro Donohue Cornejo Journal: World J Clin Cases Date: 2022-10-06 Impact factor: 1.534